• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Coronavirus

To jumpstart the COVID vaccine race, the U.K. considers ‘challenge trials’ exposing people to the virus

By
James Paton
James Paton
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
James Paton
James Paton
and
Bloomberg
Bloomberg
Down Arrow Button Icon
September 24, 2020, 4:50 AM ET

The U.K. government is considering carrying out the first studies that would deliberately expose healthy people to the coronavirus in a bid to accelerate the development of a vaccine.

The idea of challenge trials has gained momentum as the pathogen has spread around the world, sparking a debate over what kind of sacrifice is acceptable and the benefits the tests could bring. A growing number of volunteers have signed up to take part in such studies should researchers decide to proceed.

“We are working with partners to understand how we might collaborate on the potential development of a Covid-19 vaccine through human-challenge studies,” a government representative said Wednesday in an email. “These discussions are part of our work to research ways of treating, limiting and hopefully preventing the virus so we can end the pandemic sooner.”

Waiting for participants to become exposed to the illness to figure out whether a vaccine works can take months or even years. Challenge tests can hasten the work by placing volunteers in the path of the virus, though scientists are still learning about a pathogen that has killed almost 1 million people in just months.

Such tests also raise ethical questions about exposing people to a potentially fatal virus, and whether some test subjects would receive a placebo for control purposes.

The government declined to provide further details, including about which vaccines would be involved. U.K.-funded studies are expected to begin in January at a facility in London, the Financial Times reported earlier. In Britain, the University of Oxford is working with AstraZeneca Plc on a Covid vaccine, one of the front-runners in the global effort. Imperial College London is also working on an experimental inoculation.

About the Authors
By James Paton
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon
0

Most Popular

placeholder alt text
Real Estate
The 'Great Housing Reset' is coming: Income growth will outpace home-price growth in 2026, Redfin forecasts
By Nino PaoliDecember 6, 2025
2 days ago
placeholder alt text
AI
Nvidia CEO says data centers take about 3 years to construct in the U.S., while in China 'they can build a hospital in a weekend'
By Nino PaoliDecember 6, 2025
2 days ago
placeholder alt text
Economy
The most likely solution to the U.S. debt crisis is severe austerity triggered by a fiscal calamity, former White House economic adviser says
By Jason MaDecember 6, 2025
1 day ago
placeholder alt text
Economy
JPMorgan CEO Jamie Dimon says Europe has a 'real problem’
By Katherine Chiglinsky and BloombergDecember 6, 2025
1 day ago
placeholder alt text
Big Tech
Mark Zuckerberg rebranded Facebook for the metaverse. Four years and $70 billion in losses later, he’s moving on
By Eva RoytburgDecember 5, 2025
3 days ago
placeholder alt text
Politics
Supreme Court to reconsider a 90-year-old unanimous ruling that limits presidential power on removing heads of independent agencies
By Mark Sherman and The Associated PressDecember 7, 2025
16 hours ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.